Purpose: This phase II neoadjuvant study investigated whether nab-paclitaxel, carboplatin, and bevacizumab given prior to neoadjuvant doxorubicin/cyclophosphamide produced higher pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) compared with historical results achieved with standard anthracycline/taxane regimens.
Triple negative breast cancer (TNBC) is generally more chemosensitive, with higher pathologic complete response (pCR) rates after neoadjuvant therapy compared with other subtypes of breast cancer [1, 2] . Patients with TNBC who achieve a pCR have survival outcomes similar to the other breast cancer subtypes, but a greater risk of relapse if residual disease remains [2] . pCR has been shown to correlate with improved disease free (DFS) and overall survival (OS) in breast cancer [3, 4] . However, with standard anthracycline plus taxane regimens only about 20-25% of hormone receptor-negative breast cancer patients achieve a pCR [3, 5] . Further optimization of neoadjuvant treatment for TNBC is needed.
In patients with metastatic breast cancer (MBC), every-3-week nab-paclitaxel was superior to solventbased paclitaxel [6] . Basal-like breast cancers overexpress SPARC (secreted protein acidic and rich in cysteine) [7] .
In preclinical models, SPARC transports albumin-bound (nab-) paclitaxel intracellularly, via SPARC-GP60-Caveolin 1 binding, that may contribute to antitumour efficacy [8] . A higher frequency of BRCA-1 deficiency and other DNA damage repair defects in sporadic basallike breast cancer may make these tumours more sensitive to platinum drugs [9, 10] . Carboplatin plus solvent-based paclitaxel was evaluated in first line MBC, with higher response rates (RRs) compared to single agent paclitaxel [11, 12] . A phase I trial demonstrated the feasibility of combining nabpaclitaxel with carboplatin in solid tumours, including MBC [13] . Angiogenesis also plays an integral role in the growth and progression of breast cancer. In the E2100 trial, bevacizumab added to weekly paclitaxel significantly improved RRs and median progression free survival (PFS) in HER2-negative MBC [14] .
Based on this efficacy data in the metastatic setting, we designed the current trial to evaluate whether integrating nab-paclitaxel, carboplatin, and bevacizumab into an anthracycline-based neoadjuvant regimen would increase pCR rates with an acceptable safety and tolerability profile in patients with operable TNBC.
Patients and Methods:
Patient Eligibility Eligible patients were women ≥18 years of age with palpable (≥ 2cm) and operable, histologically confirmed, estrogen receptor (ER)-and progesterone receptor (PR)-negative (per local testing, eligibility confirmed centrally by review of pathology reports), and negative for HER2 (0 or 1+ on immunohistochemistry and/or documented nonamplification by fluorescence in situ hybridization) invasive ductal carcinoma of the breast, with or without clinically positive nodes. Clinically positive nodes were identified by physical examination or imaging. Pathologic confirmation of clinically positive nodes such as with a fine needle aspiration (FNA) was not required but allowed. ECOG performance status of 0-1, baseline cardiac ejection fraction ≥ lower limit of normal (LLN), adequate hematologic, renal and hepatic function were also required. Sentinel node biopsy prior to treatment was discouraged but not prohibited.
Major exclusion criteria included metastatic, T4, clinical N2b or N3, or inflammatory breast cancer; significant cardiac disease, uncontrolled hypertension, thrombotic or hemorrhagic events, coagulation disorders, another primary malignancy except treated basal or squamous cell carcinoma of the skin or in situ cervical cancer, unless disease-free for ≥ 5 years. All patients provided written informed consent, and the study was approved by the institutional review board at each site.
Study Design and Treatment
This was a phase II, open label, single arm nonrandomized study. All patients were required to undergo pretreatment breast biopsies for correlative analyses. Whole blood and plasma samples were also collected at pre-specified time points. Patients received four 28-day cycles of intravenous nabpaclitaxel (100 mg/m2 on days 1, 8 and 15 over 30 minutes) plus carboplatin (area under the curve [AUC] 6 on day 1 over 30 minute), plus bevacizumab (10 mg/kg on days 1 and 15; over 90 minutes for cycle 1, over 60 and 30 minutes for cycle 2 and beyond respectively). (Figure 1 ).
Figure 1: Treatment schema
This was followed by four 14-day cycles of intravenous AC [doxorubicin (60 mg/m2 on day 1 over 15 minutes), cyclophosphamide (600 mg/m2 on day 1 over 30 minutes)], and bevacizumab (10 mg/kg on day 1 for the first 2 cycles only). Surgery, including axillary staging, was performed between 2 and 6 weeks after the last dose of AC. Postoperatively, patients received eight 28 day cycles of bevacizumab (10 mg/kg on days 1 and 15) after a minimum of 4 weeks from surgery and evidence of complete wound healing.
During preoperative cycles 5-8, prophylactic granulocyte colony stimulating factor (G-CSF) was required. During cycles 1-4, G-CSF was not to be used as primary prophylaxis, but was allowed for febrile neutropenia, and as secondary prophylaxis for subsequent cycles. Dose modification criteria for hematologic and nonhematologic toxicities are described in Supplementary Appendix 1. Mid-study, in compliance with the FDA guidance issued around changes in creatinine methodology and carboplatin dosing, a GFR cap of 125 mL/min was implemented for the Calvert formula so that the maximum dose of carboplatin for any patient was not to exceed 900 mg [15] .
No dose reductions of bevacizumab were allowed, and treatment was held if the chemotherapy component was delayed. Protocol-specified therapy was discontinued for progressive disease, unacceptable toxicity, withdrawal of consent, or physician judgment.
Efficacy and Safety Assessments
The primary endpoint of the study was the in-breast pCR rate after 8 cycles of preoperative therapy, defined as no histologic evidence of invasive tumour cells (with or without carcinoma in situ) in the surgical breast specimen. Secondary objectives included near-pCR rate (≤ 0.5cm of residual invasive tumour in the breast), and pCR breast + nodes (no invasive tumour cells in the breast, axillary and sentinel nodes). Clinical response was assessed by physical examination, with clinical complete response (cCR), clinical partial response (cPR) and stable disease (SD) defined by RECIST (Response Evaluation Criteria in Solid Tumours) version 1.0 (Supplementary Appendix 2). Rate of breast conserving surgery, safety and tolerability were also assessed, including cardiac safety with echocardiogram or MUGA scans required on all patients at pre-specified time points. Toxicities were graded using the NCI Common Terminology Criteria of Adverse Events version 3.0.
Statistical Considerations
A 60 patient sample size, assuming a 10% attrition rate, was calculated based on an estimated pCR rate of 25% with a standard taxane plus anthracycline regimen in ER-negative, HER2-negative tumours in earlier studies. A sample size of 57 patients would be required to show an increase in pCR rate to 40%, to test this 1-sided hypothesis with approximately 80% power and a type I error rate (alpha) ≤ 0.05. The efficacy population was defined as all patients who underwent definitive breast surgery and was used for the efficacy analyses of cRR and pCR. The evaluable population was defined as all patients who received at least 75% of the total protocol defined preoperative treatment cycles and for whom pathological response data were available. The safety population included all patients who received at least 1 dose of study treatment. Statistical analyses were descriptive.
Results:

Patient Characteristics
Forty-two of 60 planned patients were enrolled between January 2009 and January 2013, and received treatment on study. At the prevailing accrual rate, it would have required an additional 12-18 months to enroll the remaining evaluable patients provided no other competing studies were to open during the same time period, so accrual was closed at that point. Baseline characteristics are described in Table 1 . Thirty-eight patients proceeded to surgery, and constitute the efficacy population, 4 patients came off study prior to surgery (2 for patient decision, 1 for disease progression and 1 for atypical chest pain); 36 patients received ≥75% of the required preoperative therapy (≥6 cycles) and comprise the evaluable population. The postoperative portion of the study is still ongoing, and the present analysis is restricted to the reporting of the primary end point of pCR after preoperative treatment.
Treatment Delivery
Among the 38 patients that constitute the efficacy population, 29 patients (76%) missed at least one dose of nab-paclitaxel out of a total of 12 planned doses over 4 cycles. The median dose intensity/week of nab-paclitaxel, averaged over 4 cycles was 68.75 mg/m2 (37.5-75 mg/m2), which was 92% of the planned dose intensity/week/cycle (75 mg/m2). The median dose intensity delivered for the other agents was 100% of planned. Two patients required a dose reduction of nab-paclitaxel to dose level -1 (80 mg/m2), and 4 patients required reduction of carboplatin to dose level -1 (AUC 5) for hematologic toxicity. Two patients did not complete at least 75% of the planned cycles prior to proceeding to surgery due to hematologic toxicities.
Treatment Response
In the efficacy population, an in-breast pCR (primary endpoint) was observed in 22 patients (58%; 95% CI: 41%-74%); 19 patients (50%; 95% CI: 33%-67%) experienced pCR in both breast and nodes. An additional 3 patients (8%) experienced a near-pCR in the breast, while residual tumour > 0.5 cm was found in 13 patients (34%). Similar results were observed in the evaluable population (Table 2) . Of the 23 patients that were clinically node positive at baseline, 20 were evaluable for the pCR end point. Twelve of these 20 patients (60%) achieved a pN0 status (pathologically negative nodes) at surgery. An additional 3 patients had micrometastatic disease in the nodes (pN1mi). A cCR was observed in 29 of 38 patients (76%) in the efficacy population, 5 (13%) achieved a cPR, and 3 (8%) had SD (Table 2) . Response rates were similar in the evaluable population.
Toxicity
The majority of adverse events (AEs) were grade 1/2 (57% grade 1; 29% grade 2; 12% grade 3; 2% grade 4). Ten of 42 patients (24%) experienced at least 1 serious adverse event (SAE) related to study treatment, with a total of 23 SAEs (Supplemental Table 1 ).
The most frequent AEs (all grades) were anemia (81%), neutropenia (81%), nausea (76%), fatigue (71%), and thrombocytopenia (60%) ( Table 3 ). The most frequent grade 3/4 AEs were neutropenia (57% grade 3, 31% grade 4), thrombocytopenia (29% grade 3), and anemia (21% grade 3, 2% grade 4). Despite the high rate of neutropenia, only 1 patient developed neutropenic fever requiring IV antibiotics. Peripheral neuropathy was reported in 31% of patients (5% grade 3). Grade 1/2 hypertension and proteinuria occurred in 36% and 10% of patients respectively, and there were no reported grade 3/ 4 events.
Cardiac function was assessed at baseline and prior to surgery. Of the 42 patients, paired echocardiograms or MUGA scans were available for 37. The median ejection fraction (EF) at baseline was 62.4% (range 53.0 -80.0), compared with 60.2% (range 48.7 -70.7) at the completion of preoperative treatment. Six patients experienced a drop in EF ≥10%, but not to below the institutional LLN. There were no cases of clinical congestive heart failure reported.
Discussion:
To our knowledge, this is the first report of a combination of weekly nab-paclitaxel plus carboplatin followed by AC with concurrent bevacizumab in the neoadjuvant treatment of TNBC. In this study, we observed a 58% in-breast pCR rate and 50% of patients achieved a pCR in both breast and nodes.
To put our results in context, we examined recently presented data from two randomized phase II trials evaluating similar neoadjuvant regimens for early stage breast cancer. (Table 4) In the GeparSixto trial, a significant increase in the pCR rate (breast plus nodes), from 36.9% to 53.2% (p = 0.005), was observed with the addition of carboplatin for patients with TNBC. All patients received bevacizumab [16] . Similarly, the Cancer and Leukemia Group (CALGB) 40603 trial in a 2 x 2 randomized design, reported an absolute difference of 14% in the in breast pCR rate with carboplatin versus no carboplatin (60% versus 46%, p= 0.0018), and 11% (59% versus 48%, p =0.0089) with bevacizumab versus no bevacizumab [17] . No significant treatment interaction was found between carboplatin and bevacizumab (p=0.52).
Intrinsic subtyping based on PAM50 showed an association between higher pCR rates in the basal subtype of TNBC for bevacizumab, but a similar predictive value was not demonstrated for carboplatin. No definite mRNA gene expression signatures predictive for carboplatin benefit were revealed [18] .
The lack of a control arm in our study, the presence of bevacizumab in both arms in the GeparSixto trial, and the lack of power to compare the carboplatin arm alone to the control arm without carboplatin or bevacizumab in the CALGB 40603 trial makes it difficult to definitively conclude the contribution of carboplatin to pCR rates. However, these trials including our study provide a consistent signal of similar significant increases in pCR rates with carboplatin added to a taxane plus anthracycline backbone in TNBC. In addition, in the ISPY-2 trial, the combination of carboplatin plus veliparib plus standard neoadjuvant chemotherapy predicted for a pCR rate of 52% in the hormone receptornegative/HER2-negative subgroup compared with 26% in the control group based on a Bayesian prediction model [18] . A large phase 3 randomized study is evaluating this combination in TNBC (clinicaltrials.gov NCT02032277).
J Cancer Allied Spec 2016;2(1):3 of a standard anthracycline/taxane neoadjuvant regimen (38% versus 29%; P=.001), although the rate of grade 3/4 peripheral neuropathy was also increased [19] . Notably, the subset of patients with TNBC appeared to derive the greatest benefit from nabpaclitaxel in this study (Odds Ratio 2.69, pCR rates 48% vs. 29% p < 0.001). It is likely that within TNBC, certain molecular subsets (e.g. the mesenchymal or mesenchymal stem cell-like) [20] with high expression of genes encoding for epithelial mesenchymal transition (e.g. SPARC), could potentially be more sensitive to nab-paclitaxel compared to sb-paclitaxel. Correlative analyses to be conducted in the near future on the preoperative biopsy samples from our study and studies like the GeparSepto trial may lend some useful insight into this.
Bevacizumab has been evaluated for neoadjuvant breast cancer treatment in randomized trials that included subsets of TNBC patients (Table 4) . Though small increases in pCR rates were observed in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-40 and GeparQuinto trials with the addition of bevacizumab to chemotherapy, the benefit in the TNBC subset was not consistent (Table 4 ) [21, 22] . Correlative data from the CALGB 40603 study do lend a worthwhile hypothesis for a basal like intrinsic subtype, higher expression of a proliferation signature, and lower expression of estrogen signature as being predictive of increased pCR rates with bevacizumab. These will require further large scale validation prior to being considered for stratification of patients for treatment decisions [18] .
In our trial, patients also received an additional eight cycles of bevacizumab after completion of surgery.
Results of this phase are not yet mature and will be reported in the future. However, one year of adjuvant bevacizumab plus chemotherapy for patients with TNBC in the phase III BEATRICE trial produced no improvement in invasive disease-free survival (DFS) or OS compared to chemotherapy alone [23] . Similarly, the recently presented Eastern Cooperative Oncology Group (ECOG) 5103 adjuvant trial in HER2-negative breast cancer did not show a DFS advantage for 6 or 12 month of post-operative bevacizumab added to chemotherapy versus chemotherapy alone [24] . These data together do not support a significant role of bevacizumab in the treatment of early stage TNBC at this point in time.
Correlative biomarkers from these large adjuvant studies might identify potential subgroups of patients likely to derive benefit.
With regard to tolerability, the majority of AEs in our study were grade 1/2, with a 14% rate of grade 3 or 4 events. Despite the high rate of grade 3/4 neutropenia, the rate of febrile neutropenia was very low, likely due to the frequent use of G-CSF after cycle 1. The rates of neutropenia are consistent with other trials combining both carboplatin and bevacizumab with standard neoadjuvant chemotherapy. Also consistent among the different trials is the observation that the addition of carboplatin with or without bevacizumab interferes with the delivery of all 12 planned weekly doses of the taxane. In our study, and in CALGB 40603 [17] , approximately 60-65% of the patients received 11-12 planned doses of the taxane when both carboplatin and bevacizumab were also administered. In the GeparSixto trial, the mean relative total dose intensity (RTDI) of all treatments in the TNBC cohort was 80% without and 71% with carboplatin (p < 0.0001) [16] . The mean RTDI increased from 68% to 72% when the dose of carboplatin was reduced from an AUC of 2 to AUC 1.5, accompanied by a lower rate of treatment discontinuation [16] .
This study along with the other recent neoadjuvant studies discussed above underscore the heterogeneity of the TNBC population, and not all patients benefit from the addition of platinum agents and other targeted therapies. The additional toxicity and the compromised delivery of the standard backbone drugs need to be kept in mind when advocating for more intensified neoadjuvant regimens for all patients with TNBC. Future studies should focus on evaluating distinct molecular subsets with differing sensitivity to cytotoxic and biologic agents [20, 25] . For instance, an analysis of homologous recombination deficiency (HRD) in breast cancer identified one-third of TNBCs (36%) that could potentially benefit from DNA damaging drugs like the platinum compounds alone or in combination with poly (ADP ribose) polymerase (PARP) inhibitors based on HRD [26] . The PrECOG study 0105 evaluated the combination of carboplatin plus gemcitabine plus iniparib neoadjuvantly in TNBC patients with or without germline BRCA mutations [27] . A higher pCR rate was observed for tumours with a higher HRD score irrespective of germline BRCA status. Sub-classification of responders and non-responders into molecular subsets showed the highest responses in the immunomodulatory subset, and no responses in the luminal androgen receptorlike subset. Recent data from the GeparSixto trial correlated a higher expression of immune related genes and tumour infiltrating lymphocytes with higher pCR rates [28] . The development of multiple T cell check point inhibitors might offer an opportunity to further enhance response to neoadjuvant chemotherapy for patients in the near future.
Finally, in a recently published pooled analysis of 12 neoadjuvant breast cancer studies the prognostic correlation of pCR with event free (EFS) and OS was shown for TNBC and HER2-positive breast cancer treated with trastuzumab [29] . Though the individual trial level data failed to show a correlation between the treatment effect on pCR and EFS or OS, the authors concluded that the heterogeneous study populations and the small absolute difference in pCR rates between the treatment and control arms in the majority of these trials were unlikely to be sufficient to impact a change in EFS and OS. More effective therapies in homogeneous subsets of breast cancer that produce larger absolute differences in pCR rates, as reported by our group and other contemporary trials could be speculated to produce a meaningful treatment effect on EFS and OS when analyzed in the future.
In conclusion, our study has demonstrated substantially higher pCR rates with the combination of nab-paclitaxel plus carboplatin followed by AC, with concurrent bevacizumab, compared with historic rates associated with anthracycline-taxane regimens alone. Correlative data from this study and the other recent studies exploring similar combinations will hopefully allow selection of certain subsets of TNBC patients for whom further investigation of this regimen would be warranted. Longer follow-up of our study and others is needed to establish the impact of these novel regimens on survival outcomes in TNBC.
